1-20 of 3113
surrogate endpoints
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children

Clinical Trials & Observations
Leonardo R. Brandao, Manuela Albisetti, Jacqueline Halton, Lisa Bomgaars, Elizabeth Chalmers, Lesley G. Mitchell, Ildar Nurmeev, Pavel Svirin, Tomas Kuhn, Ondrej Zapletal, Igor Tartakovsky, Monika Simetzberger, Fenglei Huang, Zhichao Sun, Jörg Kreuzer, Savion Gropper, Martina Brueckmann, Matteo Luciani
Blood blood.2019000998.
DOI: https://doi.org/10.1182/blood.2019000998
Published: 2019
Journal Articles

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Clinical Trials & Observations
Nobuko Hijiya, Alexey Maschan, Carmelo Rizzari, Hiroyuki Shimada, Carlo Dufour, Hiroaki Goto, Hyoung Jin Kang, Terri Guinipero, Zeynep Karakas, Francisco Bautista, Stéphane Ducassou, Keon Hee Yoo, Christian Michel Zwaan, Frédéric Millot, Paola Aimone, Alex Allepuz, Sara Quenet, Florence Hourcade-Potelleret, Sabine Hertle, Darintr Sosothikul
Blood (2019) 134 (23): 2036–2045.
DOI: https://doi.org/10.1182/blood.2019000069
Published: 2019
Includes: Supplemental data
Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD
Blood (2019) 134 (Supplement_2): LBA-6.
DOI: https://doi.org/10.1182/blood-2019-132629
Published: 2019
Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Andrew H. Wei, MBBS, FRACP, FRCPA, PhD, Hartmut Döhner, MD, Christopher Pocock, MBBS, Pau Montesinos, MD PhD, Boris Afanasyev, MD DSci, Hervé Dombret, MD, Farhad Ravandi, MD, Hamid Sayar, MD MSc, Jun Ho Jang, MD PhD, Kimmo Porkka, MD, Dominik Selleslag, MD, Irwindeep Sandhu, MD, Mehmet Turgut, MD, Valentina Giai, MD, Yishai Ofran, MD, Merih Kizil Cakar, MD, Aida Botelho de Sousa, MD, Justyna Rybka, MD PhD, Chiara Frairia, MD, Lorenza Borin, MD, Germana Beltrami, MD, Jaroslav Cermak, MD PhD, Gert J. Ossenkoppele, MD PhD, Ignazia La Torre, MD, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, CL Beach, PharmD, Gail J. Roboz, MD
Blood (2019) 134 (Supplement_2): LBA-3.
DOI: https://doi.org/10.1182/blood-2019-132405
Published: 2019
Journal Articles

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Alexander Röth, Wilma Barcellini, Shirley D'Sa, Yoshitaka Miyakawa, Catherine M Broome, Marc Michel, David J. Kuter, Bernd Jilma, Tor Henrik Anderson Tvedt, Stella Lin, Xiaoyu Jiang, Caroline Reuter, William Hobbs, Sigbjørn Berentsen
Blood (2019) 134 (Supplement_2): LBA-2.
DOI: https://doi.org/10.1182/blood-2019-132490
Published: 2019
Journal Articles

CD19-Directed Fast CART Therapy for Relapsed/Refractory Acute Lymphoblastic Leukemia: From Bench to Bedside

Cheng Zhang, Jiaping He, Li Liu, Jishi Wang, PhD, Sanbin Wang, Ligen Liu, Lei Gao, Li Gao, Yao Liu, Peiyan Kong, Jia Liu, Yu Han, Yongliang Zhang, Zhe Sun, Xun Ye, Yan He, Lianjun Shen, MD PhD, Wei Cao, Xi Zhang
Blood (2019) 134 (Supplement_1): 1340.
DOI: https://doi.org/10.1182/blood-2019-128006
Published: 2019
Journal Articles

A Phase 2 Study of Glasdegib for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients with High Risk of Post-Allogeneic Stem Cell Transplantation Relapse

Andrew Kent, MD PhD, Sumithira Vasu, MDMBBS, Derek Schatz, Natalie Monson, Steven Devine, MD, Clayton Smith, MD, Jonathan A Gutman, MD, Daniel A Pollyea, MD
Blood (2019) 134 (Supplement_1): 1311.
DOI: https://doi.org/10.1182/blood-2019-127418
Published: 2019
Journal Articles

Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Johannes Duell, MD, Kami J. Maddocks, MD, Eva González-Barca, MD PhD, Wojciech Jurczak, MD PhD, Anna Marina Liberati, Sven de Vos, MD PhD, Zsolt Nagy, MD PhD, Aleš Obr, MD PhD, Gianluca Gaidano, MD PhD, Pau Abrisqueta, MD PhD, Marc André, Martin Dreyling, MD, Tobias F Menne, MD PhD FRCPath, Maren Dirnberger-Hertweck, PhD, Johannes Weirather, PhD, Sumeet Ambarkhane, MD MBBS, Gilles A. Salles, MD PhD
Blood (2019) 134 (Supplement_1): 1582.
DOI: https://doi.org/10.1182/blood-2019-122573
Published: 2019
Journal Articles

Immune Priming with Single-Agent Nivolumab Followed By Combined Nivolumab & Rituximab Is Safe and Efficacious for First-Line Treatment of Follicular Lymphoma; Interim Analysis of the '1 st FLOR' Study

Allison Barraclough, Geoff Chong, Michael Gilbertson, Andrew Grigg, Leonid Churilov, Tineke Fancourt, David Ritchie, MD PhD, Rachel Koldej, Rishu Agarwal, Kate Manos, Charmaine Smith, Kristen Houdyk, Joanne Hawking, Eliza Hawkes
Blood (2019) 134 (Supplement_1): 1523.
DOI: https://doi.org/10.1182/blood-2019-123908
Published: 2019
Journal Articles

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Namrata S Chandhok, MD, Wei Wei, MD, Stephanie Halene, MD, Thomas Prebet, MD PhD
Blood (2019) 134 (Supplement_1): 1374.
DOI: https://doi.org/10.1182/blood-2019-130033
Published: 2019
Journal Articles

Long-Term Efficacy and Safety Results of CT-P10 and Reference Rituximab in Patients with Newly Diagnosed Advanced Stage Follicular Lymphoma: Phase III Updated Study Results with Median Follow-up of 40 Months

Christian Buske, MD PhD, Larry W Kwak, MD PhD, Wojciech Jurczak, MD PhD, Juan-Manuel Sancho, MD PhD, Edvard Zhavrid, MD PhD, Jin Seok Kim, MD PhD, Jose Angel Hernandez-Rivas, MD PhD, Aliaksandr Prokharau, MD PhD, Mariana Vasilica, MD PhD, Rajnish Nagarkar, MD PhD, Gayane Tumyan, DMSc, MD PhD, Won-Seog Kim, MD PhD, Michinori Ogura, MD PhD, Sang Joon Lee, PhD, Sung Hyun Kim, PhD, Keum Young Ahn, PhD
Blood (2019) 134 (Supplement_1): 1528.
DOI: https://doi.org/10.1182/blood-2019-126379
Published: 2019
Journal Articles

Long-Term Efficacy and Safety of Copanlisib in Multiply Relapsed or Refractory Patients with Marginal Zone Lymphoma

Martin Dreyling, MD, Panayiotis Panayiotidis, MD, George A Follows, MD PhD, Luigina Mollica, MD FRCPC, PhD, Arnon Nagler, MD MSc, Muhit Özcan, MD, Armando Santoro, Don Stevens, MD, David Trevarthen, MD, Florian Hiemeyer, MSc, Li Liu, PhD, Jose Garcia-Vargas, MD, Barrett H Childs, MD, Pier Luigi Zinzani, MD PhD
Blood (2019) 134 (Supplement_1): 1531.
DOI: https://doi.org/10.1182/blood-2019-121932
Published: 2019
Journal Articles

Superior Outcomes in Relapsed/Refractory Childhood B-ALL Than Adult Patients with CD19 CAR-T Cell Therapy: A Single-Center Pilot Prospective Study of 23 Patients

Tingting Li, Luting Luo, Jinhua Ren, Xiaofeng Luo, Zhihong Zheng, Hao Zheng, Zhizhe Chen, Gangxiong Huang, Ting Yang, Jianda Hu
Blood (2019) 134 (Supplement_1): 1353.
DOI: https://doi.org/10.1182/blood-2019-129758
Published: 2019
Journal Articles

Long Term Follow-up of a Phase II Study of Cladribine with Concurrent Rituximab in Patients with Hairy Cell Leukemia Variant

Dai Chihara, MD PhD, Evgeny Arons, PhD, Maryalice Stetler-Stevenson, MD PhD, Constance M. Yuan, MD PhD, Hao-Wei Wang, MD PhD, Hong Zhou, Mark Raffeld, MD, Liqiang Xi, MD, Seth M. Steinberg, PhD, Julie Feurtado, RN, Lacey James-Echenique, CRNP, Wyndham Wilson, MD, Raul C. Braylan, MD, Katherine R. Calvo, MD PhD, Irina Maric, MD MSci, Alina Dulau-Florea, MD, Robert J. Kreitman, MD
Blood (2019) 134 (Supplement_1): 1536.
DOI: https://doi.org/10.1182/blood-2019-124515
Published: 2019
Journal Articles

Effect of Ara-C on T-Cell Function and Flotetuzumab Activity in Pediatric Acute Myeloid Leukemia

Anilkumar Gopalakrishnapillai, PhD, Anne Kisielewski, BS, Ezio Bonvini, MD, John Muth, MS, Jan K Davidson-Moncada, MD PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc
Blood (2019) 134 (Supplement_1): 1387.
DOI: https://doi.org/10.1182/blood-2019-126791
Published: 2019
Journal Articles

Dose Optimization of Duvelisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Selection of Regimen for the Dose-Expansion Phase

Steven M. Horwitz, MD, Neha Mehta-Shah, MD, Barbara Pro, MD, Eric D Jacobsen, MD, Carla Casulo, Jonathan E. Brammer, MD, Jeff Haney, Hagop Youssoufian, MD, David T. Weaver, PhD, Michael Baglio, PharmD, Jasminder Soto, Narayana Narasimhan, Jasmine Zain, MD
Blood (2019) 134 (Supplement_1): 1567.
DOI: https://doi.org/10.1182/blood-2019-121401
Published: 2019
Journal Articles

Daratumumab Monotherapy for Patients with Relapsed or Refractory (R/R) Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type: Updated Results from an Open-Label, Single-Arm, Multicenter Phase 2 Study

Hui-qiang Huang, Won-Seog Kim, MD PhD, Ming Yao, MD, Tae Min Kim, MD PhD, DocHyun Yoon, MD PhD, Seok-Goo Cho, MD PhD, Hyeon-Seok Eom, MD PhD, Su-Peng Yeh, MD, Soon Thye Lim, MBBS, MRCP, FAMS, Yuqin Song, Shizhou Liu, MD, Grace Gao, Lijia Zhang, Min Qing, Ming Qi, MD PhD, Jin Seok Kim, MD PhD, Yok Lam Kwong, MD FRCP, Jie Jin, MD PhD, Yuankai Shi, MD PhD, Jun Zhu, MD PhD
Blood (2019) 134 (Supplement_1): 1568.
DOI: https://doi.org/10.1182/blood-2019-123446
Published: 2019
Journal Articles

A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Naval G. Daver, MD, Weiguo Zhang, MD PhD, Richard Graydon, MD PhD, Vikas K Dawra, MBA, PhD, Jingdong Xie, PhD, Prasanna Kumar, PhD, Michael Andreeff, MD PhD
Blood (2019) 134 (Supplement_1): 1389.
DOI: https://doi.org/10.1182/blood-2019-122585
Published: 2019
Journal Articles

A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404

Jonathon B. Cohen, MDMS, Craig A. Portell, MD, Mehdi Hamadani, MD, Opeyemi Jegede, PhD, Catherine Diefenbach, MD, Kevin A. David, MD, Christopher D. Fletcher, MD, Daniel J. Landsburg, MD, Brad S. Kahl, MD
Blood (2019) 134 (Supplement_1): 1541.
DOI: https://doi.org/10.1182/blood-2019-127494
Published: 2019
Journal Articles

Impact of Rituximab in the Clinical Outcomes of Hairy Cell Leukemia: A Retrospective Single-Institution Analysis

Kristen Gonter-Aubin, DO, Daniel Alan Kerr, MD PhD, Ashley Rose, MD, Thanh Lana Nguyen, MDBS, Julio C. Chavez, MD, Javier Pinilla Ibarz, MD PhD
Blood (2019) 134 (Supplement_1): 1542.
DOI: https://doi.org/10.1182/blood-2019-129028
Published: 2019